UNSPSC 51312805: Methdilazine

This classification denotes a vasodilating agent with the molecular formula C18H20N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4Q13LY9Z8X, chemically known as 10h-phenothiazine, 10-((1-methyl-3-pyrrolidinyl)methyl)- but generally known as methdilazine, which bears US NIH Compound Identifier 14677. European Medicines Agency schedules Methdilazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08844MIG.

UNSPSC 51312805 Methdilazine is a Commodity code that encompasses prescription and over-the-counter pharmaceutical products procured by state and local health agencies, public health departments, and cooperative purchasing alliances to support community health initiatives, pharmacy benefit programs, and emergency response systems. The actual buying under this code spans generic multi-source pharmaceuticals, naloxone and drug deactivation systems for harm reduction and overdose response, and direct-to-manufacturer prescription fulfillment arrangements negotiated outside traditional pharmacy benefit manager and group purchasing organization channels. State and local issuing bodies soliciting under the code include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The work involves both traditional commodity procurement—bulk purchases of identified pharmaceutical products with specific National Drug Codes, packaging configurations, and pricing models—and emerging direct-contracting models where states seek to establish relationships with manufacturers to improve prescription fulfillment efficiency and manage costs through value-based or outcomes-based agreements.

Recent activity shows geographically dispersed solicitation across Florida, Texas, Minnesota, and Oregon. Representative recent opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) to gather vendor capability information on direct-to-manufacturer prescription programs, and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) to establish multiple contracts for generic pharmaceuticals and over-the-counter products across participating state and local facilities, requiring vendors to maintain relationships with authorized wholesalers and comply with cGMP and DSCSA certification standards.